Benzimidazoles
Lansoprazole Impurity Standard, British Pharmacopoeia (BP) Reference Standard, MilliporeSigma™ Supelco™
This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets, has been developed and issued under the Authority of the issuing Pharmacopoeia.
Fenbendazole 98.0+%, TCI America™
CAS: 43210-67-9 Molecular Formula: C15H13N3O2S Molecular Weight (g/mol): 299.348 MDL Number: MFCD00144301 InChI Key: HDDSHPAODJUKPD-UHFFFAOYSA-N Synonym: Methyl [5-(Phenylthio)benzimidazol-2-yl]carbamate, [5-(Phenylthio)benzimidazol-2-yl]carbamic Acid Methyl Ester PubChem CID: 3334 ChEBI: CHEBI:77092 IUPAC Name: methyl N-(6-phenylsulfanyl-1H-benzimidazol-2-yl)carbamate SMILES: COC(=O)NC1=NC2=C(N1)C=C(C=C2)SC3=CC=CC=C3
Albendazole 98.0+%, TCI America™
CAS: 54965-21-8 Molecular Formula: C12H15N3O2S Molecular Weight (g/mol): 265.33 MDL Number: MFCD00083232 InChI Key: HXHWSAZORRCQMX-UHFFFAOYSA-N Synonym: albendazole,albenza,eskazole,valbazen,zentel,albendazol,proftril,albendazolum,bilutac,zental PubChem CID: 2082 ChEBI: CHEBI:16664 IUPAC Name: methyl N-[6-(propylsulfanyl)-1H-1,3-benzodiazol-2-yl]carbamate SMILES: CCCSC1=CC=C2N=C(NC(=O)OC)NC2=C1
Oxibendazole 98.0+%, TCI America™
CAS: 20559-55-1 Molecular Formula: C12H15N3O3 Molecular Weight (g/mol): 249.27 MDL Number: MFCD00133728 InChI Key: RAOCRURYZCVHMG-UHFFFAOYSA-N Synonym: Methyl (5-Propoxy-1H-benzo[d]imidazol-2-yl)carbamate, (5-Propoxy-1H-benzimidazol-2-yl)carbamic Acid Methyl Ester PubChem CID: 4622 IUPAC Name: methyl N-(6-propoxy-1H-benzimidazol-2-yl)carbamate SMILES: CCCOC1=CC2=C(C=C1)N=C(N2)NC(=O)OC
Albendazole sulfone
CAS: 75184-71-3 Molecular Formula: C12H15N3O4S Molecular Weight (g/mol): 297.33 MDL Number: MFCD00600775 InChI Key: CLSJYOLYMZNKJB-UHFFFAOYSA-N Synonym: albendazole sulfone,unii-1uic88380g,methyl 5-propylsulfonyl 2-benzimidazolecarbamate,methyl 5-propylsulfonyl-1h-benzimidazol-2-yl carbamate,methyl-5-propylsulfonyl-1h-benzimidazol-2-yl carbamate,5-propylsulfonyl-2-benzimidazolecarbamic acid methyl ester,methyl 6-propylsulfonyl-1h-benzo d imidazol-2-yl carbamate,methyl n-5-propane-1-sulfonyl-1h-1,3-benzodiazol-2-yl carbamate,2-benzimidazolecarbamic acid, 5-propylsulfonyl-, methyl ester PubChem CID: 53174 ChEBI: CHEBI:80620 IUPAC Name: methyl N-[6-(propane-1-sulfonyl)-1H-1,3-benzodiazol-2-yl]carbamate SMILES: CCCS(=O)(=O)C1=CC=C2N=C(NC(=O)OC)NC2=C1
![Medchemexpress LLC Carbamic acid, N-[6-(phenylthio)-1H-benzimidazol-2-yl]-, methyl ester | 43210-67-9 | 99.9% | 500 MG](https://assets.fishersci.com/TFS-Assets/CCG/product-images/default.jpg-250.jpg)
Medchemexpress LLC Carbamic acid, N-[6-(phenylthio)-1H-benzimidazol-2-yl]-, methyl ester | 43210-67-9 | 99.9% | 500 MG
Fenbendazole is an orally active benzimidazole anthelmintic agent with a broad antiparasitic range. It functions as a microtubule destabilizing agent by binding to tubulin and disrupting the tubulin microtubule equilibrium. It stabilizes the transcriptional activator HIF-1α, exhibits efficient anti-proliferative activity, and induces apoptosis. This agent also causes cell-cycle arrest and mitotic cell death, demonstrating antitumor activity.
- Orally active benzimidazole anthelmintic agent
- Broad antiparasitic range
- Functions as a microtubule destabilizing agent
- Stabilizes transcriptional activator HIF-1α
- Exhibits anti-proliferative activity
- Induces apoptosis and causes cell-cycle arrest
- Demonstrates antitumor activity
Medchemexpress LLC (R)-Omeprazole (sodium) | 161796-77-6 | 98.1% | 25 MG
(R)-Omeprazole sodium is a gastric acid resistant compound that inhibits gastric acid secretion. It is metabolized in vivo, primarily by cytochrome P450 enzymes, and its interaction with mannitol may affect its bioavailability in formulations. It exhibits reversible direct and metabolism-dependent inhibition of CYP2C19.
- Gastric acid resistant compound
- Inhibits gastric acid secretion
- Metabolized by cytochrome P450 enzymes
- Reversible direct and metabolism-dependent inhibition of CYP2C19
- For research use only
Medchemexpress LLC (R)-Omeprazole sodium | 161796-77-6 | 98.1% | 50 MG
(R)-Omeprazole sodium is a gastric acid resistant compound that inhibits gastric acid secretion. Its metabolism in vivo is primarily affected by cytochrome P450 enzymes. The interaction between (R)-Omeprazole sodium and mannitol may affect its bioavailability in formulations. It exhibits reversible direct and metabolism-dependent inhibition of CYP2C19.
- Gastric acid resistant compound
- Inhibits gastric acid secretion
- Metabolized primarily by cytochrome P450 enzymes
- Interaction with mannitol may affect bioavailability
- Exhibits reversible direct and metabolism-dependent inhibition of CYP2C19
Medchemexpress LLC (R)-Omeprazole sodium | 161796-77-6 | 98.1% | 100 MG
(R)-Omeprazole sodium is a gastric acid resistant compound that inhibits gastric acid secretion. It is primarily metabolized by cytochrome P450 enzymes in vivo, and its interaction with mannitol may affect its bioavailability in formulations. This compound exhibits reversible direct and metabolism-dependent inhibition of CYP2C19. It is intended for research use only.
- Gastric acid resistant compound
- Inhibits gastric acid secretion
- Metabolism affected by cytochrome P450 enzymes
- May interact with mannitol affecting bioavailability
- Exhibits reversible direct and metabolism-dependent inhibition of CYP2C19
- For research use only
Medchemexpress LLC (R)-Omeprazole (sodium) | 161796-77-6 | 98.1% | 250 MG
(R)-Omeprazole sodium is a gastric acid resistant compound that inhibits gastric acid secretion. It is primarily metabolized in vivo by cytochrome P450 enzymes. Interactions with mannitol may affect its bioavailability in certain formulations.
- Inhibits gastric acid secretion
- Metabolized by cytochrome P450 enzymes
- Interacts with mannitol
- Reversibly inhibits CYP2C19 directly and metabolism-dependently
- For research use only
Medchemexpress LLC Omeprazole | 73590-58-6 | 100.0% | C17H19N3O3S | 500 MG
Omeprazole is a proton pump inhibitor (PPI) used to treat acid-related gastrointestinal disorders. It works by competitively inhibiting CYP2C19 activity. Additionally, Omeprazole inhibits the growth of Gram-positive and Gram-negative bacteria and is identified as a potent brain penetrant neutral sphingomyelinase (N-SMase) inhibitor. This acid-labile compound is used in the treatment of various conditions including dyspepsia, peptic ulcer disease, and gastroesophageal reflux disease.
- Proton pump inhibitor
- Competitively inhibits CYP2C19 activity (Ki of 2 to 6 μM)
- Inhibits growth of Gram-positive and Gram-negative bacteria
- Potent brain penetrant neutral sphingomyelinase (N-SMase) inhibitor
- Inhibits gastric acid secretion
- Used for treating acid-related gastrointestinal disorders
Apexbio Technology LLC Omeprazole 73590-58-6 10mM (in 1mL DMSO)
Omeprazole (73590-58-6) is a small-molecule inhibitor targeting H K -ATPase an enzyme essential for gastric acid secretion It is designed to inhibit the proton pump thereby reducing active transport of H ions into the gastric lumen Omeprazole exerts its biological activity primarily through irreversible binding to the H K -ATPase enzyme In in vitro studies Omeprazole demonstrates inhibitory activity with an IC value of approximately 5 8 M against purified H K -ATPase and an IC of 0 16 M in assays evaluating histamine-induced gastric acid production Based on these pharmacological properties Omeprazole holds research potential in the investigation of acid-mediated gastrointestinal conditions and related pathways
Apexbio Technology LLC Omeprazole 73590-58-6 100mg
Omeprazole (73590-58-6) is a small-molecule inhibitor targeting H K -ATPase an enzyme essential for gastric acid secretion It is designed to inhibit the proton pump thereby reducing active transport of H ions into the gastric lumen Omeprazole exerts its biological activity primarily through irreversible binding to the H K -ATPase enzyme In in vitro studies Omeprazole demonstrates inhibitory activity with an IC value of approximately 5 8 M against purified H K -ATPase and an IC of 0 16 M in assays evaluating histamine-induced gastric acid production Based on these pharmacological properties Omeprazole holds research potential in the investigation of acid-mediated gastrointestinal conditions and related pathways
Medchemexpress LLC Omeprazole | 73590-58-6 | 99.9% | 345.42 | 100 MG
Omeprazole is a proton pump inhibitor (PPI) used for treating acid-related gastrointestinal disorders. It competitively inhibits CYP2C19 activity and inhibits the growth of both Gram-positive and Gram-negative bacteria. Additionally, it is a potent brain penetrant neutral sphingomyelinase (N-SMase) inhibitor and an exosome inhibitor.
- Proton pump inhibitor (PPI)
- Competitively inhibits CYP2C19 activity
- Inhibits growth of Gram-positive and Gram-negative bacteria
- Potent brain penetrant neutral sphingomyelinase (N-SMase) inhibitor
- Exosome inhibitor
- Inhibits gastric acid secretion
- Acid-labile compound
Selleck Chemical LLC Omeprazole Sodium
Omeprazole Sodium is the sodium salt form of omeprazole which is a proton pump inhibitor and suppresses gastric acid secretion Omeprazole Sodium is a metabolism-dependent inhibitor (MDI) of CYP2C19